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Abstract In cultured rat hepatocytes the key gluconeogenic enzyme phosphoenolpyruvate c rboxykinase (PCK) is known to be induced by glucagon 
via an elevation of cAMP. Prostaglandin E2has been shown to antagonize the glucagon-activated cAMP formation, glycogen phosphorylase activity 
and glucose output in hepatocytes. It was the purpose of the current investigation tostudy the potential of PGE2 to inhibit the glucagon-induced 
expression ofPCK on the level of mRNA and enzyme activity. PCK mRNA and enzyme activity were increased by 0.1 nM glucagon to a maximum 
after 2 h and 4 h, respectively. This increase was completely inhibited if 10/tM PGE2 was added concomitantly with glucagon. This inhibition by 
PGE 2 of glucagon-induced PCK activity was abolished by pertussis toxin treatment. When added at the maximum of PCK mRNA at 2 h, PGE: 
accelerated the decay of mRNA and reduced enzyme activity. This effect was not reversed by pertussis toxin treatment. Since in liver PGE2 is derived 
from Kupffer cells, which play a key role in the local inflammatory esponse, the present data imply that during inflammation PGE2 may reduce 
the hepatic gluconeogenic capacity via a G~-linked signal chain. 
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1. Introduction 
Prostaglandins are involved in short-term regulation of liver 
carbohydrate metabolism. They are produced by non-par- 
enchymal liver cells and seem to mediate the hepatic glucose 
mobilization i response to inflammatory stimuli by e.g. zymo- 
san, immune complexes, platelet activating factor and anaphyl- 
atoxins ([1] and references therein). Prostaglandins increased 
lnsP 3 formation, glycogen phosphorylase activity and glucose 
output in hepatocyte cultures and suspensions [1-3]. This glyco- 
genolytic effect was mediated by prostaglandin F2a and prosta- 
glandin E2 receptors of the EPI subtype that are linked to 
phospholipase C by a pertussis toxin-insensitive G-protein [1]. 
In addition, prostaglandin E2 inhibited the glucagon-stimulated 
cAMP formation [4], glycogen phosphorylase activity [1] and 
glucose mobilization from glycogen [5,6] and gluconeogenesis 
[1] in hepatocytes. This glucagon-antagonistic effect was medi- 
ated by prostaglandin E2receptors of the EP 3 subtype [1], that 
are linked to adenylate cyclase by a pertussis toxin-sensitive 
G~-protein [7]. Since glucagon also stimulated prostaglandin 
synthesis in Kupffer cells [8], it seems to be possible, that the 
prostaglandin E2-mediated inhibition of the glucagon-stimu- 
lated cAMP formation ot only operates within the short-term 
regulation of metabolism but also within the control of gene 
expression and thus represents a general intrahepatic feedback 
loop for the limitation of glucagon action. 
In cultured rat hepatocytes the expression of the key regula- 
tory enzyme of hepatic gluconeogenesis, phosphoenolpyruvate 
carboxykinase (PCK), is increased by glucagon on the tran- 
scriptional level [9]. It had been shown in rat hepatoma cells 
that the activation of the PCK gene is mediated by the pro- 
moter-bound transcription factor cAMP regulatory element 
binding protein (CREB), which upon cAMP-dependent phos- 
phorylation confers transcriptional activation to the PCK gene 
[10,11]. Therefore, prostaglandin E 2 might also attenuate the 
* Corresponding author. Fax: (49) (551) 395 960. 
glucagon-induced activation of PCK gene expression. The cur- 
rent investigation supports this hypothesis, ince the glucagon- 
induced increase in PCK mRNA level and enzyme activity was 
totally abolished, if prostaglandin E2was added concomitantly 
with glucagon. 
2. Materials and methods 
2.1. Animals and chemicals 
Cells were prepared from male fed Wistar ats (200-300 g) (Winkel- 
mann, Borchen, Germany). Chemicals were analytical grade and pur- 
chased from commercial sources. Collagenase A, culture medium 
M 199, the digoxygenin-labeling mix and the digoxygenin detection kit 
were from Boehringer (Mannheim, Germany). Hormones were sup- 
plied by Serva (Heidelberg, Germany) and molecular biology products 
by Life Technologies (Eggenstein, Germany). Supported nitrocellulose 
(BA 85) was from Schleicher & Schfill (Dassel, Germany) and culture 
dishes from Greiner (Niirtingen, Germany). PGE 2 was a product of 
Cascade (Reading, UK). The cAMP radioimmunoassay w spurchased 
from Amersham Buchler (Braunschweig, Germany). 
2.2. Experimental design 
Hepatocytes were prepared by the collagenase p rfusion technique 
[12] and cultured on plastic dishes (1 × 106 cells/dish; 60 mm diameter) 
for 48 h with 2.5 ml medium/dish in the presence of 100 nM dexa- 
methasone and 0.5 nM insulin added as a 'growth factor' for culture 
maintenance. During the first 4 h of culture 4% fetal calf serum was 
present, which was then removed by a medium change. The cells were 
supplied with fresh medium after another 20 h of culture. After 48 h 
of culture induction experiments were started by washing the cells twice 
with insulin-free, but dexamethasone-containing medium. The culture 
was then continued in fresh insulin-free, dexamethasone-containing 
medium for the times indicated in the presence of 0.1 nM glucagon. 
PGE 2 was added either simultaneously with or 2 h after glucagon to a 
final concentration f 10 gM. Cells were harvested atthe time points 
indicated. Total RNA was prepared for Northern blot analysis by 
phenol extraction. PCK enzyme activity was determined in postmito- 
chondrial supernatants [13]. cAMP was determined after extraction 
with 10 mM HC1 containing 100/tM isobutyl methyl xanthine to inhibit 
phosphodiesterase. 
2.3. Tools and assays 
Northern blots detecting hepatocyte cytosolic PCK were carried out 
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with digoxygenin-labelled antisense cRNA probes. These were pre- 
pared with the DIG-labelling kit according to the supplier's manual 
(Boehringer) by transcription with DNA-dependent RNA T3 polymer- 
ase. PCK cRNA was synthesized from the HindlII-linearized plasmid 
pBS-PCK, which contained a Pstl 1.2 kb cDNA fragment coding for 
rat PCK [14]. Hybrids were detected according to the protocol of 
Boehringer and were quantified by video densitometry. For detection 
of PCK mRNA 20 pg of total RNA were applied to electrophoresis. 
cAMP was determined with a ~251-radioimmunoassay kit according 
to the instructions of the manufacturer. 
3. Results and discussion 
3.1. Inhibition by PGE e of the glucagon-induced increase in PCK 
mRNA and enzyme activity 
Glucagon (0.1 nM) added with fresh medium after 48 h of 
culture increased PCK mRNA levels about 6-fold (Fig. 1, upper 
left). This increase was transient with a maximum after 2 h. It 
reached nearly pre-stimulatory levels again after another 4 h. 
The increase in mRNA was preceded by a sharp increase in 
cAMP within 2 min reaching a maximum 2-fold over basal after 
5 min (Fig. 2). cAMP remained elevated at about 1.5-fold over 
basal for 6 h (not shown). Probably due to the medium change, 
mRNA levels also increased slightly and transiently in control 
hepatocytes which were not treated with glucagon. PGE 2 (10 
pM)  added concomitantly with glucagon, prevented both, the 
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Fig. 1. Time course of the increase in PCK mRNA and enzyme activity 
by glucagon and PGE 2 in primary hepatocyte cultures. Cells were 
cultured for 48 h in presence of 0.5 nM insulin and 100 nM dexa- 
methasone. Cells were washed twice with insulin-free dexamethasone- 
containing medium. Induction was then started by addition of fresh 
medium with or without 0.1 nM glucagon and/or 10/tM PGE2 (left 
panel). Alternatively, induction was started by the addition of fresh 
medium with or without 0.1 nM glucagon and PGE z was added 2 h later 
to a final concentration of 10/.tM (right panel). After the intervals 
indicated cells were harvested for determination f PCK mRNA levels 
and enzyme activity, mRNA was quantified in northern blots by video 
densitometry. PCK enzyme activity was determined by a standard assay 
in the cytosol. Values are means + S.E.M. of duplicates of 3 cell prep- 
arations. 
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Fig. 2. Inhibition by PGE 2 of the glucagon-induced cAMP formation 
in hepatocytes. Hepatocytes were cultured for 48 h in presence of 0.5 
nM insulin and 100 nM dexamethasone. C lls were washed twice with 
insulin-free dexamethasone-containing medium. Induction was then 
started by addition of fresh medium with or without 0.1 nM glucagon 
(Ggn) and/or 10 pM PGE2. At the times indicated medium was re- 
moved, cells were lysed in liquid nitrogen and then homogenized in 10 
mM HCI containing 1mM IBMX. The homogenate was centrifuged 
and cAMP was determined in the supernatant by radio immunoassay. 
Values are means + S.E.M. of 6 experiments of 2 cell preparations. 
glucagon-induced rise in cAMP (Fig. 2) and mRNA (Fig. 1, 
upper left). Under these conditions cAMP concentrations and 
PCK mRNA levels were in the range of control cells. PCK 
mRNA levels in hepatocytes receiving PGE2 alone were below 
control evels. In these cells no transient increase in mRNA was 
observed. PGE 2 alone caused only a slight transient increase in 
cAMP with a maximum after 2 min, which returned to basal 
after 5 min (Fig. 2). This is in contrast o previous findings with 
freshly isolated hepatocytes or hepatocytes after 24 h in primary 
culture, where PGE 2 had no effect on basal cAMP levels [1]. 
Following the increase in mRNA levels PCK enzyme activity 
increased in glucagon-stimulated cells to a maximum between 
4 and 6 h. This increase in enzyme activity was completely 
abolished if PGE2 was added concomitantly with glucagon. In 
these cells and in cells receiving no hormones or PGE 2 alone 
enzyme activity remained constant at basal levels throughout 
6 h (Fig. 1, lower left). 
The glucagon-induced increase in PCK mRNA has previ- 
ously been shown to be due to transcriptional activaton. The 
Y-promoter of the PKC gene contains a cAMP responsive 
element (CRE). A regulatory protein, CREB, binds to the CRE 
and stimulates transcription after cAMP-dependent phospho- 
rylation [10,11]. Thus, glucagon induced PCK mRNA and en- 
zyme activity by an increase in cAMP which was prevented by 
simultaneous application of PGE z. 
3.2. Attenuation by pertussis toxin of the inhibition by PGE e of 
glucagon-induced PCK enzyme activity 
Previous studies have shown that the inhibition by PGE2 of 
the glucagon-stimulated cAMP formation in hepatocytes is 
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Fig. 3. Attenuation by pertussis toxin of the inhibition by PGE 2 of 
glucagon-induced PCK enzyme activity. Hepatocytes were cultured for 
48 h in presence of 0.5 nM insulin and 100 nM dexamethasone and, 
where indicated, 100 ng/ml pertussis toxin for the last 18 h. Cells were 
washed twice with insulin-free dexamethasone-containing medium. In- 
duction was then started by addition of fresh medium with or without 
0.1 nM glucagon and/or 10 ~tM PGE 2 (control, glucagon (Ggn), PGE 2 
(PGE) and glucagon + PGE 2 (Ggn + PGE)). Alternatively, induction 
was started by addition of fresh medium with or without 0.1 nM 
glucagon; PGE 2 was then added 2h later to a final concentration f 10 
/.tM (PGE 2 h, Ggn + PGE 2 h). After 6 h of induction ceils were 
harvested and PCK enzyme activity was determined in the cytosol by 
a standard assay. Values are means + S.E.M. of three cell preparations. 
Statistics: Students t-test for paired samples: a, P < 0.01; b, P < 0.05. 
mediated via PGE 2 receptors of the EP 3 subtype, which are 
linked to adenylate cyclase via a pertussis toxin sensitive Gi 
protein [1]. The inhibition by PGE2 of glucagon-induced PCK 
activity was abolished in hepatocytes treated with pertussis 
toxin for 18 h prior to the experiment (Fig. 3). Therefore, the 
inhibition of glucagon-induced PCK activity by PGE2 was also 
mediated via a pertussis toxin sensitive inhibitory G protein. 
3.3. Acceleration by PGE 2 of  the degradation of  glucagon- 
induced PCK mRNA 
IL6, the major acute phase mediator in the liver, accelerated 
the degradation of PCK mRNA [15]. It seemed, therefore, 
possible, that PGE2 might not only inhibit the glucagon-in- 
duced PCK transcription but might also increase PCK mRNA 
degradation. Hence, PGE2 was added at the maximum of glu- 
cagon-induced PCK mRNA 2 h after induction. The degrada- 
tion of PCK mRNA was measured as PCK mRNA remaining 
in the absence of a transcriptional inhibitor. This was manda- 
tory because the use of inhibitors of transcription stabilized 
PCK mRNA [9]. Moreover, this was permissive, since after 
2 h of glucagon treatment the transient increase in gene tran- 
scription had already returned to basal [9]. If PGE2 was added 
2 h after glucagon, the degradation of glucagon-induced PCK 
mRNA was nearly doubled (Fig. 1, upper right), cAMP-levels, 
that had remained elevated were slightly reduced by addition 
of PGE2 2 h after glucagon administration ( ot shown). In 
hepatocytes that received PGE2 2 h after glucagon the glu- 
cagon-induced nzyme activity continued to increase until 4 h, 
reaching a maximum about 25% below the maximum with 
glucagon alone and then started to decline between 4 and 6 h 
(Fig. 1, lower right). The glucagon-induced PCK-activity at 
6 h was only 60% of the activity in presence of glucagon alone. 
This effect of PGE2 was not abolished by pertussis toxin treat- 
ment (Fig. 3). Yet, the inhibition by PGE2 of the glucagon- 
induced PCK enzyme activity was no longer significant. This 
result indicates, that the reduction of glucagon-induced nzyme 
activity by PGE2 added 2 h after induction might only partially 
be due to the Gi-decrease in cAMP and that in addition, a 
different signal path might also be involved. 
3.4. Pathophysiological significance 
IL6 [15], ILlfl and TNF~ [16] have previously been shown 
to antagonize the glucagon-mediated induction of PCK in 
hepatocytes. It has been discussed that this downregulation of
the expression of the key gluconeogenic enzyme may represent 
a molecular economy which could provide additional biosyn- 
thetic capacity for acute phase protein synthesis [15]. PGE2 
appears to be a major regulatory mediator in inflammatory 
processes in the liver. PGE2 synthesis in Kupffer cells is in- 
creased by tumor necrosis factor cz (TNF~) [17]. PGE2 has been 
implicated in the feedback inhibition of TNFct [17] as well as 
the IL6 [18,19] and ILl [19] production by Kupffer cells. On 
the other hand PGE2 in combination with TNFcz or ILlfl in- 
creased NO-formation in Kupffer cells, whereas TNFcz and 
ILlfl alone were inactive [20]. 
Thus PGE 2 seems to play a dual role in liver during inflam- 
mation: First, PGE2 apparently can limit the acute phase re- 
sponse by feedback-inhibiting the production and release of 
various pro-inflammatory c tokines. Second, PGE2 can en- 
hance inflammatory responses like NO production or, as de- 
scribed here, downregulation of gluconeogenic enzymes in 
order to liberate additional synthetic apacity for acute phase 
protein production. 
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